CARDIOVASCULAR DISEASES

Pathophysiology of lipid-related disease

Summary

Alterations in lipids and lipoproteins are not only key causal factors in atherosclerotic cardiovascular disease and overall cardiovascular risk, but are also closely associated with the development of other major health conditions, such as type 2 diabetes, metabolic syndrome, obesity, Alzheimer’s disease, and certain types of cancer.

In this context, the research lines of our group focus on deepening the understanding of the role of lipid alterations in these diseases, with the aim of identifying and developing novel biomarkers and potential targeted therapies that contribute to improving diagnosis, risk stratification, and clinical management of patients.

Main lines of Research and Innovation

The group’s activity focuses on two main research lines and one emerging line, which are closely interconnected.

  1. Lipoprotein metabolism and cardiovascular risk

We focus on the study of lipoproteins, particularly remnant lipoproteins, low-density and high-density lipoproteins (LDL and HDL), and their role as potential prognostic biomarkers. We investigate their utility in supporting pharmacological and nutritional interventions aimed at correcting lipoprotein dysfunctions in patients at high cardiovascular risk, as well as in patients with endocrine cancers and Alzheimer’s disease.

In addition, we study the role of novel microRNAs as regulators of lipoprotein metabolism and atherosclerosis, and evaluate their therapeutic potential in vivo through the use of recombinant HDL.

  1. Molecular diagnosis and characterization of metabolic disorders

We develop and validate innovative analytical methods for the study of metabolic and endocrine disorders. Thanks to the high volume of samples processed and our scientific output, our laboratory has become a national reference center for the diagnosis of inherited dyslipidemias.

  1. Biomarkers in neurodegenerative diseases (emerging line)

In collaboration with the Memory Unit of the Neurology Department at Hospital de Sant Pau, we work on the development and implementation of blood-based biomarkers for the diagnosis of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and other dementias. These biomarkers enable the detection of key pathophysiological processes, support diagnosis, monitor disease progression, and evaluate treatment response.

Challenges

  • To develop and validate lipoprotein-related predictive biomarkers for diabetes and cardiovascular disease in populations at high metabolic risk, in order to improve risk stratification and personalized prevention.
  • To deepen the understanding of the molecular mechanisms regulating alterations in lipoprotein metabolism in type 1 and type 2 diabetes, with particular focus on key proteins such as ANGPTL3 and APOC3.
  • To evaluate the therapeutic potential of synthetic HDL and targeted rHDL–miRNA–based therapies in atherosclerosis regression.
  • To unravel the complex interaction between lipid metabolism and Alzheimer’s disease progression in Down syndrome, with the aim of identifying novel pathogenic mechanisms and potential therapeutic targets.

This website uses cookies to improve the browsing experience and perform analytical tasks. If you continue browsing, we understand that you agree our cookies policy. More information